By Ellen Capon (Drug Target Review)2024-07-09T10:00:17
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-06-13T13:30:40
Sponsored by NanoTemper Technologies
2023-01-06T10:25:33
Sponsored by Leica Microsystems
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-03-03T14:06:14
Sponsored by Bio-Techne
2023-03-20T13:41:33
Sponsored by Bio-Techne
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud